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Abstract 
 
Background: 
Cytomegalovirus (CMV) is the most common pathogen responsible for morbidity and 
mortality in immunosuppressed individuals. One population at high risk is solid organ 
transplant (SOT) recipients. 
Intravenous ganciclovir is the gold standard for treatment of CMV disease. Oral 
valganciclovir is a prodrug of ganciclovir, with an almost 60% oral bioavailability, 
and has recently been shown to be non-inferior to intravenous ganciclovir in the 
VICTOR study. 
The purpose of this thesis was to develop a pharmacokinetic population model to 
describe the ganciclovir plasma concentration observations in the patient population 
of the VICTOR study, after receiving oral valganciclovir for treatment of CMV 
disease. Additionally the model was to be validated, in order to make it clinically 
applicable. 
Methods: 
Of the 321 patients who were included in the VICTOR study 164 were randomized 
into the valganciclovir arm, and in 108 was the plasma concentration of ganciclovir 
measured. The development of the population pharmacokinetic model was based on 
these 108 patients. The data contained information of demographical, physiological 
and pathophysiological nature, as well as the measured drug concentrations. The 
model was constructed by use of the NONMEM version VI computer program, as 
well as PREDPP and R for subroutines and graphs, respectively. 
Results: 
A 2-compartment model with first-order absorption was found to be the overall best 
model for the data set. The ADVAN4 routine was used in combination with the 
TRANS4 subroutine. After a forward inclusion and backwards deletion procedure 
creatinine clearance and gender were significant covariates in the model. The average 
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(± SD) parameter estimates for the final model were CL/F = 12±0.05 L/h, V2/F = 
59.4±2.76 L, Q/F = 7.21±0.20 L/h, V3/F = 304±7.79 L. 
The validation procedure employed a K-fold cross-validation, as recommended by 
the FDA, and the Jackknife technique. The model appeared stable, but susceptible to 
variations in the data-set (Central volume had a range of 57.1 – 93.8 L, while 
peripheral volume had a range of 270 – 357 L. 
Conclusions: 
The model fulfills the goal of predicting ganciclovir plasma concentrations to a 
satisfying degree, especially for individually predicted concentrations, although it has 
room for improvement. It is a good basis for the further development of a PK/PD 
model that compares ganciclovir pharmacokinetics with both therapeutic effects and 
adverse events. 
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1. Background 
1.1 Pharmacokinetics 
1.1.1 Introduction 
Pharmacokinetics (PK) is the study of a drugs life in the body. From concentration 
measurements gathered from different samples, a model is constructed which 
describes how the body “treats” the drug, i.e. how it is metabolized and eliminated. 
The counterpart to pharmacokinetics is pharmacodynamics (PD), which in short is the 
study of the effects a drug has on the body [1]. 
Every drug has a so-called “therapeutic window”, illustrated in Figure 1. What this 
term means is that for every drug there is a certain range of concentrations that 
promise successful treatment, while at the same time have a sufficiently low chance 
for adverse events. If the concentration in the patient is too low, the treatment will 
fail. If the concentration is too high, the risk of adverse events is unacceptably large. 
This window exists for the majority of drugs, but for some it is quite wide, while for 
others extremely narrow. It is in particular for the ones with the narrow windows that 
pharmacokinetic monitoring is of benefit, as it is extra important to keep plasma 
concentrations within the 
acceptable range of 
concentrations [1]. 
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Figure 1: Interplay between drug-concentration and ineffective 
therapy, therapeutic effect and adverse events. 
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1.1.2 The compartment concept 
The human body is an incredibly complex system. Trying to include every element in 
the body that might influence a drug’s concentration and disposition in a model 
would quickly spiral out of both control and usefulness. 
It is interesting, therefore, that very simple models have been found quite useful in 
representing and predicting drug concentrations in the body. 
Figure 2 is an example of a 2-compartment model. A dose is given which is absorbed 
into the central compartment. From there the drug is either eliminated or distributed 
to the peripheral compartment. There is also transport back from the peripheral 
compartment and into the central one once distribution has started. Obviously, the 
body contains no such distinct compartments, but considering that the model predicts 
drug measurements in the plasma to an acceptable degree it is satisfactory. 
Furthermore, the predictions derived from using it, and its variations, are accurate. 
It is also possible to add or subtract compartments to get models that better describe 
the drug at hand. Both 1, 2 and 3-
compartmental models are quite 
common [1, 2]. 
It is also useful to differentiate 
between transfer and chemical 
compartments for some drugs, 
but this does not include 
ganciclovir. A transfer 
compartment can be thought of as 
a “place” in the body. The blood, 
for instance, is such a place. 
When substances differ chemically from each other they are said to be in different 
chemical compartments. A metabolite is chemically different from its parent drug, 
and they are therefore in different chemical compartments [1]. 
Measuring 
Compartment 
Dose 
Elimination 
Ka 
Peripheral 
Compartment 
K10 
K12 
K21 
Figure 2: Compartmental theory 
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Once again, it is not normally possible to measure the concentrations of drugs or 
metabolites at every location, or compartment, in the body. Usually one only has 
plasma-samples to work with, and has to extrapolate concentrations in other locations 
[1]. 
The site of effect of ganciclovir is within virus-infected cells. CMV usually lies 
dormant in endothelial cells, but can infect many different organs during a primary 
infection or reactivation. 
Ideally, one would measure the concentration of active drug at the site of action. 
Regretfully for science, if not for the patient, this is not usually feasible. It is often too 
difficult or too risky, if not downright terminal, to take samples from the site of 
effect. Therefore one usually measures the concentration of the drug in the blood, and 
correlates this concentration with the success or failure of treatment. 
Another bodily fluid often used for sampling is urine [1]. 
 
1.2 Population pharmacokinetics 
Population pharmacokinetics can be defined as the study of variability in plasma drug 
concentrations in a population representative of the intended target group for the 
drug. This type of study focuses on certain demographical, pathophysiological, 
physiological, therapeutical and other kinds of features that vary between individuals, 
and which are known to possibly be responsible for the alterations in drug 
concentrations inter-individually. For example, obese patients with their increased 
body-mass will in all probability have a higher distribution volume. A given amount 
of drug will therefore give a lower apparent concentration than in a patient of more 
normal weight. The reason for this kind of study is that if we find the sources of the 
variability in concentration for a certain drug, and are able to measure them, we can 
modify the dosage given to each patient, ensuring optimal therapeutic concentration 
[3, 4]. 
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Another positive side of the use of population pharmacokinetics is that it allows one 
to gain quite extensive and integrated information on pharmacokinetics from sparse 
data. It is also usable on dense data, and even mixed sparse/dense data. This makes it 
possible to analyze and gain information from studies of unbalanced design, and also 
some that would otherwise have been excluded because they do not normally lend 
themselves to pharmacokinetic analysis. It is also quite useful in situations where the 
drug in question has a very narrow window of therapeutic effect, and the dose will 
have to be adjusted individually [4]. 
Even though the term was not originally coined with this in mind, population 
pharmacokinetics has come to mean the design, execution and analysis of studies 
with limited pharmacokinetic data [3]. 
Traditionally, pharmacokinetic studies have had very strict exclusion criteria, wanting 
groups of subjects that were as homogenized as possible. This was because the main 
focus was on finding the mean drug concentration, and any inter-individual 
variability was seen as something that must be avoided. The study designs and 
control schemes were also similarly strict. The variability in concentration is of high 
importance in the clinical use of drugs, and as these studies suppressed them it was 
not possible to find the factors responsible for the differences, nor measure them. 
It is usual to divide variability into inter-individual and residual variability. The inter-
individual variability is a biological imperative, and stems from the simple fact that 
every person is biologically different from practically all others. This leads in most 
cases to variations in plasma drug concentrations which can be quite large. 
Residual variability is a combination of sources for variation, such as intra-individual 
differences, inter-occasional differences, and errors made in measurement, dosing and 
modeling [1, 4, 5]. From this one can surmise that some of the more important 
differences between population pharmacokinetics (PK) and traditional 
pharmacokinetics are the collection of individual data relevant to the measuring of 
inter-individual variability, the measuring of said variability (both during 
development and the subsequent evaluation of drugs), the explanation of the true 
variability by pharmacological factors logically capable of inducing these changes, 
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and last but not least the estimation of the remaining unexplained variability. 
There will almost always be a remaining unexplained variability, both inter-
individually and intra-individually. This may be because of time-dependent 
pharmacological variations within each patient, errors during sampling, or possibly 
other unforeseen events. One must also remember that all these mathematical 
calculations are just a simplification of reality, unable to perfectly explain everything. 
Regardless, it is imperative for the optimal treatment of patients to have a sense of 
understanding for how these unexplained differences behave, and the magnitude of 
them. 
 
 
1.2.1 Naïve pooled data approach 
As the name implies, the Naïve Pooled Data Approach (NPD) is a method where all 
the data from the different patients is treated as if it came from a single patient. 
This model is easy to use, and requires little computational power. It can also be used 
on a variety of data, from experimental data to routine pharmacokinetic data. There 
are of course drawbacks, and these lie mainly in the simplification process. By 
pooling, one looses the detailed information of each individual and variation between 
individuals. This can lead one to believe that the data is neat and simple, while the 
fact may be that each patient varies widely in their observed concentrations. There 
may also be trends in individual curves which are smothered in the multitude, and 
therefore become unrecognizable. The method works well when there are low 
variations between individuals, but this is rarely the case with humans, which limits 
its usefulness. 
Parameter estimates will be means, and one will not gain any estimates of spread. In 
addition, if the number of observations varies between patients, this will negatively 
affect the reliability of the method [6]. 
This approach was not utilized in this thesis, and will therefore not be discussed 
further. 
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1.2.2 The two-stage approach 
The two-stage approach is a traditional pharmacokinetic analysis, and was designed 
to be used in the data-rich environment of previously mentioned traditional 
pharmacokinetic investigations. The first part entails using nonlinear regression to 
estimate an individual’s pharmacokinetic parameters from the concentration-time 
data gathered. As mentioned, this must be rich data. These estimates are then used in 
the second step to calculate statistics such as mean parameter estimates, variance and 
covariance of said parameter estimates, as well as for searching for dependencies 
between the parameters in question. 
It is quite possible to get decent and relatively unbiased estimations of parameters 
using this two-stage approach, even though random effects are usually exaggerated in 
practical situations. The catch is the necessity of a data-rich situation [4, 6]. 
This method was not used in this thesis, therefore it will not be further discussed. 
 
1.2.3 Nonlinear mixed-effects modeling 
The reason for the words “mixed-effect” in the name of this method comes from the 
fact that a model built this way will contain a fixed structure and a randomness block. 
The fixed structure contains what we know, or suspect, of the models behavior and 
interaction with other parameters. Knowing that a drug is eliminated predominantly 
by the renal pathway might lead us to include renal clearance as a scaling parameter 
for the observed concentration of drug. 
The randomness block is there to describe the residual variance. This variance will 
always be present, to a greater or lesser extent. It is the biological changes in a body 
from day to day, the effect a diet has on a person, the compliance of a patient, and 
any possible errors in the sampling procedure. The common factor is that they cannot 
be predicted in advance. Together, these fixed effects and random effects are called 
mixed-effects [2]. 
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The use of nonlinear mixed-effects modeling on population pharmacokinetics makes 
it possible to design less extensive studies than what is needed for a two-stage 
approach, and still give valid results. These designs are less restrictive to the patients, 
which makes it easier both for the participants and the conductors. When one finds 
oneself in a situation with sparse or mixed data where a two-staged model cannot be 
used, nonlinear mixed-effects modeling is a very handy tool for bringing answers out 
of the material at hand. 
The nonlinear mixed-effects approach uses the population as a whole, not the 
individual, as basis for the estimation of parameters, and how these interact with 
relevant covariates. Even so, the individual is not lost in the masses, and through the 
estimates of population parameters and their variability, and not least the covariates 
that influence these parameters, it is possible to make predictions regarding individual 
patients [4]. 
 
1.2.4 Sampling designs in population pharmacokinetic 
investigations 
In population pharmacokinetics we talk about, roughly, three sampling approaches: 
Single-trough sampling, multiple-trough sampling and full population PK sampling. 
These different designs give an increasing amount of pharmacokinetic information in 
that order. 
In single-trough, a single blood-sample is taken from each patient right before they 
get each new dose. At this point the drug concentration will be at its lowest in relation 
to the normal oscillation between doses. This design requires a larger mass of 
patients, and also a stricter regimen, to be able to supply valid data. It is, though, 
quite possible to estimate the mean trough concentration, and its variability, in the 
population. If the design-criteria are not met, the variability-estimate will be 
contaminated by other random factors than purely pharmacokinetic ones. 
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In multiple-trough design, two or more samples are required from each patient near 
the trough of his/her concentration curve. This design makes it possible to distinguish 
inter-individual variability from other random factors, and also allows the study of 
each patient in greater detail, for instance correlating drug-concentration with 
different patient characteristics. The design also necessitates a smaller patient-base 
than the single-trough design. 
The full population PK sampling design is also known as “experimental population 
pharmacokinetic design” or “full pharmacokinetic screen”. It requires samples to be 
drawn at, usually, minimum 3-4 times following one dose interval. This gives an even 
more complete set of information regarding the patients, and allows not only the 
estimation of PK parameters and variability of drug in the population when using the 
nonlinear mixed-effects approach, but is also capable of delving into the relationships 
between the concentration and patient characteristics of both demographic, 
physiological an pathophysiological nature [4]. 
 
1.2.5 Population PK modeling using NONMEM 
NONMEM is a computer program designed to help construct models utilizing the 
nonlinear mixed effects approach. In particular it was developed with 
pharmacokinetic models in mind. It was the first such program made to analyze large 
quantities of pharmacokinetic data, and to achieve linearization it employed a so-
called first-order (FO) Taylor series expansion in regard to the random effect 
variables ηi and εij. This is the default estimation method. NONMEM also uses two 
alternatives to this; first-order conditional estimation (FOCE) and the Laplacian 
methods. FOCE is a FO expansion about conditional estimates (empirical Bayesian 
estimates) of the inter-individual random effects. The Laplacian method on the other 
hand uses second-order expansions about the conditional estimates of the random 
effects [6]. 
A model built with NONMEM will contain a fixed structure and a randomness block, 
as mentioned earlier for models built using the nonlinear mixed-effects modeling 
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method. One does, however, differentiate between two types of variance. There is 
inter-individual variance, which is the result of the simple fact that we are not all 
alike, even physiologically. And then there is residual variance, which is the “noise”, 
or true errors, as well as intra-individual variance [2]. 
NONMEM is, regardless of its many strengths and versatility, not a particularly user-
friendly program [7]. To build a model for a dataset one will need to make two files. 
The first is the data-file, which is basically all the data written into a text-file. One 
must follow some guidelines on how it is written though. 
The second is the control-file, and this is the true model. Here the parameters and 
errors are defined, as well as supplied with starting estimates [2]. 
The parameters and the inter-individual variance are coded like this: 
Equation 1:   𝑃𝑖𝑗 = 𝑃𝑇𝑉𝑗 × 𝐸𝑋𝑃(𝜂𝑖𝑗 )  
Pij is the j-th parameter for the i-th individual, PTVj is the population “typical value” of 
the j-th parameter, and ηij is a random variable for the i-th individual on the j-th 
parameter. It has a distribution of 0 and a variance of ωij
2
. 
Intra-individual variance is coded similarly: 
Equation 2:   𝑌 = 𝑌𝑇𝑉 + 𝜀  
Here Y is the observed value of the parameter, YTV is its true value, and ε is a random 
variable representing the intra-individual error with a distribution of 0 and a variance 
of σ2. 
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The residual variability is mainly described by three different types of equations: 
additive, proportional (also known as constant coefficient of variation) and 
exponential [2]. Here are examples, in order: 
Equation 3:   𝑌 = 𝑌𝑇𝑉 + 𝜀  
Equation 4:   𝑌 = 𝑌𝑇𝑉 ×  1 + 𝜀   
Equation 5:   𝑃𝑖𝑗 = 𝑃𝑇𝑉𝑗 × 𝐸𝑋𝑃(𝜂𝑖𝑗 )  
It is also possible to combine these into mixed equations, like for instance: 
Equation 6:   𝑌 = 𝑌𝑇𝑉 ×  1 + 𝜀1 + 𝜀2     
 
The Objective Function Value (OFV) describes how good a model is at fitting the 
observed data. It does this by assuming that the model is correct, and asks how 
probable is it to get data like that which has been observed if the model is true. It 
employs the -2 log likelihood, or -2LL equation: 
Equation 7:  −2 log 𝐿 = 𝑛log 2π +   log⁡(σi
2 +
 Yi−^Yi 
2
σ i
2  
n
i=1  
By minimizing this value, one increases the likelihood of the model being a good fit 
for the data. To minimize -2LL one cannot do anything about the part: 𝑛log(2𝜋), 
seeing as this is a constant. However it is possible to minimize the part:  
  log⁡(σi
2 +
 Yi−^Y i 
2
σ i
2  
n
i=1  This part is also known as the “extended least squares” 
objective function. NONMEM looks for parameter estimates that will give the 
smallest possible -2LL. 
Now, this number does not say anything of interest by itself. What it does is let us 
compare models trying to describe the same data. By subtracting the lowest OFV 
from the highest OFV from two models, one can see if it is significantly better than 
the other. This is because the difference follows a chi-squared distribution, with 
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degrees of freedom equal to the difference of parameters between the models. For 
instance, if there is 1 degree of freedom, a difference of 3.84 between the OFV’s is 
significant at p<0.05. 
This is what makes -2LL such a useful value, because it is quite simple to subtract to 
numbers in the search for significance. However, OFV’s cannot be compared 
between datasets. A model with an OFV of 10.000 might fit a data-set better than a 
model with an OFV of 350 fits another data-set. Also, one should not add more than 1 
or 2 parameters at a time, as this will make the comparison of models unjustified. 
A final thought is that OFV is not a perfect guide. One must also evaluate the 
goodness of fit of the model, the complexity and the stability (as well as the run-
time). A model may for instance be chosen because of its reliability, even though it is 
statistically less significant than another. There are also other ways to evaluate how 
well the model actually predicts the observations. This is essential for good model-
building, one must not rely on a single method for evaluation [2, 6]. 
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1.3 Cytomegalovirus 
Human cytomegalovirus (CMV, or HCMV) is a double-stranded DNA virus from the 
Herpesviridae family of approximately 220 kb, found only in humans. It can be found 
in all secretions from the body. As a member of this particular viral family, it 
possesses their unique ability to cause a latent infection which can lie dormant until it 
reactivates later on. It is also possible to be re-infected with a new strain, so immunity 
is not granted [8-11]. 
CMV is a present infection in between 60-90% of the world’s population, but in 
developed countries the rate is estimated at 30-70%. The exact rate is dependent on 
both social differences, as well as geographical location. In a healthy human being 
this will usually be a benign infection, with no visible symptoms [8, 11]. 
The virus can be transmitted from person to person in a number of ways. Since all 
bodily fluids contain the pathogen, the transmission may be both sexually and non-
sexually. Blood transfusions may of course also contain CMV, although screening 
measures have reduced the likelihood of this happening. The virus can also be 
transferred from mother to child, either during pregnancy or after birth through 
breastfeeding. And lastly, it may be transferred from donor to recipient in a 
transplanted organ [11, 12]. 
CMV is a very common pathogen in populations with a reduced immune defense 
system. It is the most common virus to infect, or re-activate from latency, in patients 
who have undergone solid organ transplants, and who therefore have reduced 
defensive capabilities. In fact, it is the leading pathogen causing morbidity, mortality 
and graft rejection in this population. Those at highest risk are the so-called “D+/R-“-
patients, those who get an organ from a seropositive donor, but are themselves 
seronegative. It can affect many parts of the body; pneumonitis, hepatitis, encephalitis 
and illness in the gastrointestinal tract are but some of the possibilities. The survival 
of both patient and graft are also negatively affected by the presence of this disease, 
and it is particularly in the first three months after transplantation that the risk of it 
developing is greatest [9-11, 13, 14]. 
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1.4 Valganciclovir 
1.4.1 History of valganciclovir 
Valganciclovir (Ro 107 9070) was developed in an attempt to create a more easily 
administrable oral formulation of ganciclovir, because of the latter’s low 
bioavailability when taken orally, and the resulting large dose required. This would 
reduce costs and presumably also increase compliance. 
In this respect valganciclovir was a success. It is easier on the patients when 
compared to oral ganciclovir, because of the reduced size and frequency of dosage, 
not to mention when compared to intravenous ganciclovir. 
Valganciclovir has also been proposed economically attractive in comparison with 
intravenous ganciclovir therapy. This is due to many factors, from a reduced 
requirement of health workers, to less risk of treatment-requiring secondary 
infections [9, 11, 13-15]. 
1.4.2 Applications and mechanism of action 
Valganciclovir is a prodrug of ganciclovir. More specifically, it is a monovalyl ester. 
After oral administration it is transported from the intestine to the bloodstream via the 
PEPT1 peptide transporter. Thereafter it quickly reaches the liver, and both intestinal 
and liver esterases swiftly hydrolyze the prodrug to its active form, ganciclovir. It is 
however during pre-systemic absorption that most of the conversion to ganciclovir 
takes place [8, 9, 11, 13-17]. 
Ganciclovir is an antiviral agent, and achieves this by inhibiting the viral DNA-
reproduction. This is due to the nature of ganciclovir being a 2’deoxyguanosine 
(purine) nucleoside analog. A virus-protein converts this to ganciclovir 
monophosphate by means of a phosphotransferase. This is the UL97 gene product of 
CMV. After several further human transformations, the current incarnation of the 
drug, called ganciclovir triphosphate, is ready to curb some viral replication. The 
molecule is incorporated in the growth of the viral DNA, specifically at the 3’ site. 
This inclusion of ganciclovir causes the strand to lose stability, which results in 
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severe impediment of strand elongation. 
There has been reported resistance to ganciclovir, through mutations resulting in 
reduced use of the drug in DNA replication [8, 9, 11]. 
1.4.3 Adverse effects and drug interactions 
There have been observed several adverse effects in conjunction with valganciclovir. 
Anemia, diarrhea, headache, nausea, graft rejection and neutropenia have been 
observed in a few studies. Vomiting, abdominal pain, fever, thrombocytopenia, 
insomnia, peripheral neuropathy, paresthesias, tremor, back pain, hypertension, 
constipation, edema, urinary tract infection and retinal detachment, as well as several 
more, have also been reported. The last event is, curiously, also a possible event in 
retinitis caused by CMV [9, 10, 13-15, 17]. 
Since the conversion from valganciclovir to ganciclovir is very rapid, there is not 
expected to be any specific drug interactions between valganciclovir and other drugs. 
Therefore, any interactions that can take place will involve ganciclovir. Combination 
with imipenem-cilastatin may cause cramps. Probenecid reduces renal clearance of 
ganciclovir which causes significant increased exposure. Zidovudine may increase 
the risk for neutropenia. Combination with didanosine can lead to neuropathy, etc [9, 
17, 18]. 
Finally, since ganciclovir is mainly eliminated from the body by renal function, any 
patients with reduced renal capacity will need to adjust the administered dose 
accordingly [9, 13, 15, 19]. 
1.4.4 ADME of valganciclovir 
The absolute bioavailability of valganciclovir is reported to be ~60%. Oral 
formulations of ganciclovir have only been shown to give a bioavailability of 6-9%. 
A 900mg dose of valganciclovir is also reported to be equivalent to a 5mg/kg dose of 
ganciclovir intravenously, in terms of AUC [8-11, 13-17, 20]. 
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Ganciclovir is minimally bound to plasma proteins (1-2%) after absorption, and has a 
large apparent volume of distribution (>120 L) after administration of oral 
valganciclovir [21]. 
Furthermore, it has been reported that valganciclovir reaches a maximum 
concentration in the blood after 1.75-2 hours, depending on dose given [20]. 
Valganciclovir is eliminated from the body as ganciclovir, almost exclusively by 
renal excretion, through glomerular filtration and active tubular secretion. 
Elimination of ganciclovir is biphasic with the mean terminal elimination half-life 
following oral administration of valganciclovir 900 mg once daily of 6.5 hours in 
solid organ transplant recipients [21]. 
It should also be noted that there has been observed a significant increase in 
bioavailability for valganciclovir when administered in a fed state, as opposed to a 
fasted state. This increase was measured to be 30% [9]. 
 
1.4.5 Population PK models of valganciclovir in the literature 
There have in recent years been a few attempts made at making population 
pharmacokinetic models to describe ganciclovir after the administration of 
valganciclovir. 2-compartment models, in combination with 1.-order absorption, have 
been utilized in at least two studies [13, 15]. 
Apart from that, there has been observed large variations in regard to covariates 
employed in these models, seemingly without any one of them in particular rising up 
and above the rest. A notable exception is renal function, which is highly correlated 
with a good description of observations. This is not unexpected, seeing as ganciclovir 
is almost completely eliminated renally [13, 15, 19]. 
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1.5 Aim of the study 
The aim of the VICTOR study was to develop a population pharmacokinetic model 
describing the ganciclovir plasma concentrations in solid organ transplant recipients 
(SOT) receiving oral valganciclovir for treatment of CMV-disease. This model was to 
be internally validated to affirm its clinical applicability.  
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2. Methods & materials 
2.1 Design of VICTOR study 
The VICTOR (Valcyte in CMV-disease treatment of solid organ recipients) study is a 
randomized, open-label, parallel-group, active drug-controlled, multi-centre phase 
III/IV noninferiority trial in adult solid organ transplant recipients with CMV disease 
[14]. It was conducted in 42 centres in 20 different countries. Adult patients who had 
undergone solid organ transplants, and who had both virological and clinical evidence 
of CMV disease were candidates for inclusion in the study, regardless of the relative 
serostatus. CMV disease had to be confirmed by use of a local assay, following 
certain criteria. In addition, compatible symptoms had to be verified, following the 
recommendations from the American Society of Transplantation. Informed consent 
was given by each patient before inclusion in the study [14]. Exclusion criteria were 
if the disease was considered life-threatening, a history of significant adverse reaction 
to ganciclovir, valganciclovir, acyclovir or valacyclovir, if they had proven 
ganciclovir resistance, inability to take oral formulations, had received an 
investigational drug within the last 30 days or had very poor renal clearance (defined 
as a calculated creatinine clearance of <10mL/min, using the Cockcroft-Gault 
equation (appendix 7.1)). 
There were also several other drugs participants were not allowed to use during the 
study [14]. 
The participants were randomly assigned to two different treatment groups. The 
valganciclovir group received 900 mg orally twice daily during the induction period, 
while the ganciclovir group received 5 mg/kg intravenously twice daily. The 
induction period lasted for 21 days. Afterwards, both groups received 900 mg 
valganciclovir once daily for 28 days, which means until day 49. The oral doses were 
given in the form of Valcyte
®
 by Roche, each tablet containing 450 mg 
valganciclovir. 
Seeing how ganciclovir is almost exclusively eliminated renally, doses were adjusted 
according to renal function. 
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The study concluded that valganciclovir was non-inferior to ganciclovir by showing 
that viral eradication was reached in 45.1% of the valganciclovir group versus 48.4% 
in the ganciclovir group by day 21 [14]. 
2.2 Population for population pharmacokinetics 
Of the 333 patients originally screened for the study, 321 actually received at least 
one dose of study drug. These were randomly divided so that the valganciclovir group 
contained 164 patients, and the ganciclovir group contained 157 patients. Ganciclovir 
plasma concentrations were measured in 108 of the 164 patients in the valganciclovir 
group. This is the population used to develop the population pharmacokinetic model 
during this thesis. Demographic data for the 108 patients at baseline is shown in table 
1 [14]. 
 
 
Parameters Value Mean Range Median 
Number of patients 108         
Male 68         
Female 40         
Age (years)   46 18 72   
Weight (kg)   66.5 36.0 129.6   
Height (cm)   166 143 190   
Creatinine Clearance* (mL/min)   62 7 214   
Dosage given (mg)   672 450 900   
Observed concentration (μg/mL)   3.3 0.0 22.2   
Number of samples taken (n) 636         
Average number of samples per 
patient (n)   5.9 1.0 11.0   
Time after transplant (days)   366 10 9257 69 
    
    Race (n)   
    Caucasian/White 86 
    Black 3 
    Oriental 11 
    Hispanic 4 
    Other 4 
        
    
Table 1: Baseline demographics of patients in the VGC-group included in the pop-PK analysis 
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Organ transplanted (n)   
    Heart 4 
    Kidney 83 
    Kidney and Pancreas 2 
    Liver 13 
    Liver and Kidney 1 
    Lung 4 
    Pancreas 1 
        
    CMV IgG serostatus at disease start (n)   
    Positiv 61 
    Negativ 11 
    NA 36 
        
    D/R CMV IgG serostatus at Tx (n)   
    D-/R- 3 
    D-/R+ 7 
    D+/R- 16 
    D+/R+ 53 
    Missing 29 
      
     *Cockcroft-Gault formula 
     
 
2.3 Building the PK/PD model 
As previously mentioned, the computer program utilized was NONMEM. More 
specifically Version VI (GloboMax LLC, Hanover, MD, USA). The graphs were 
made using the computer program R (http://www.r-project.org/), as well as Excel 
2007
©
 (Microsoft Corporation, USA) and Minitab 15
©
 (Minitab Inc., USA). 
The first part of the building process was to create an input file. It contained all the 
data thought to be of interest to the model. This includes age, weight, creatinine 
clearance, sex and ganciclovir plasma concentration. 
The next step was to create control files to test different structural models to find out 
an appropriate model for the dataset. The models tested were from one to three 
compartments, with first-order and zero-order absorption. Elimination was assumed 
to be first-order. The choice between these models was based on which one gave the 
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lowest OFV, and at the same time was stable, gave a good fit to the data, and had a 
short run time. To be considered a statistically significant better model, there had to 
be a change in OFV of more than 3.84, which corresponds to a significant level of 
p<0.05 [2, 22]. 
The parameters employed in these models were clearance (CL/F), intercompartmental 
clearances (Qn/F),rate constant of elimination (K), absorption rate constant (KA), 
absorption lag time (ALAG), rate constant between central and peripheral 
compartments (K12, K13, K21, K31), central volume (V2/F) and peripheral volumes 
(V3/F, V4/F) [22]. 
The first-order conditional estimate (FOCE) method was used during development of 
the entire model [6]. 
2.4 Analyzing for covariates 
After having built several structural models and chosen the most appropriate one, the 
inclusion of covariates was to be tested. A covariate is a patient-specific variable, 
which ideally will adjust a predicted parameter to give an even better individual fit 
for patient data. Covariates are usually divided into two groups, continuous and 
categorical covariates. It is often the case that continuous covariates are put into 
linear equations with the parameters in question, and categorical covariates are 
handled by one or more IF/ELSE statements. Continuous covariates are also often 
centred on the population mean [23, 24]. 
The first step in the covariate phase involves the stepwise inclusion of each covariate. 
The covariates are added to the structural model one at the time, and tested against 
every possible parameter with every possible equation. If a covariate is found to give 
a significant improvement to the OFV it is included in the model, and the search 
continuous to find more significant covariates. It is usual to set the significance at 
p<0.05, which translates to a ΔOFV of >3.84 [23, 24]. 
The covariates were tested with the following general equations: 
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Equation 8:   𝑃 = 𝜃1 × 𝐶𝑂𝑉 × 𝜃2 
Equation 9:   𝑃 = 𝜃1 × 𝐶𝑂𝑉 ×  1/𝜃2  
Equation 10:  𝑃 = 𝜃1 × 𝐶𝑂𝑉
𝜃2  
P is the typical value of the parameter, 𝜃2 is the fractional change in the parameter 
with each unit of the covariate, and 𝜃1 is the typical estimated value of the parameter 
in an individual. In addition, all continuous covariates were centred on their 
population average according to the following equation [25]: 
Equation 11: 𝐶𝑂𝑉 = 𝐼𝑛𝑑𝑖𝑣𝑖𝑑𝑢𝑎𝑙 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒 𝑃𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑀𝑒𝑎𝑛 𝐶𝑜𝑣𝑎𝑟𝑖𝑎𝑡𝑒   
The categorical covariate was also tested with these IF/ELSE statements: 
𝐼𝐹  𝐶𝑂𝑉 = 1  𝑇𝐻𝐸𝑁  
𝑇𝑉 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 = 𝜃1  
𝐸𝐿𝑆𝐸  
𝑇𝑉 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 = 𝜃2  
𝐸𝑁𝐷𝐼𝐹  
Or 
𝐼𝐹  𝐶𝑂𝑉 = 1  𝑇𝐻𝐸𝑁  
𝑇𝑉 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 = 𝜃1 × 𝜃2  
𝐸𝐿𝑆𝐸  
𝑇𝑉 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 = 𝜃1 × 𝜃3  
𝐸𝑁𝐷𝐼𝐹  
Or 
𝐼𝐹  𝐶𝑂𝑉 = 1  𝑇𝐻𝐸𝑁  
𝑇𝑉 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 = 𝜃1
𝜃2   
𝐸𝐿𝑆𝐸  
𝑇𝑉 𝑝𝑎𝑟𝑎𝑚𝑒𝑡𝑒𝑟 = 𝜃1
𝜃3   
𝐸𝑁𝐷𝐼𝐹  
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After inclusion of all significant covariates into the model, the backwards deletion 
step was initiated. This step involves deleting each covariate from the new covariate 
model one at a time, and if the change in OFV is not significant it is discarded. Then 
one deletes the next covariate, until one reaches the point where there are no more 
covariates left to delete that do not give a significant change in OFV. The criterion for 
significance is set stricter at this step, and the change in OFV had to be >6.63 for a 
significance of p<0.05, and >10.9, for a significance of p<0.01. This is then called the 
final model [23, 24, 26]. 
2.5 Criteria for choice of model 
The choice of model was based upon evaluating a combination of the objective 
function value (OFV), the individual predictions versus the individual observations, 
stability of the model and the observed goodness of fit of the graphs [25, 26]. 
2.6 Validating the model 
2.6.1 K-fold cross-validation 
As advised in the FDA guideline [4], a form of data-splitting was chosen to validate 
the model. It was a K-fold cross-validation, where K was set to 10 [27, 28]. The data-
set was randomly divided into 10 subsets containing 90% of the data, as shown in 
table 2. The randomization was achieved through use of the Random Sequence 
Generator at the webpage Random.org (http://www.random.org/sequences/) [29]. 
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Group Patients removed from group 
  A B C D E F G H I J K 
1 107 102 88 75 56 92 36 15 78 66 48 
2 43 31 77 21 72 94 51 91 108 61 12 
3 39 33 26 2 45 52 50 23 47 96 73 
4 84 86 101 7 10 100 18 93 89 30 16 
5 74 57 70 76 67 65 85 79 8 58 11 
6 69 13 27 40 25 80 1 9 53 95 59 
7 82 104 54 60 81 44 90 19 62 42 97 
8 37 6 63 5 103 20 98 68 29 14 71 
9 99 35 4 32 28 55 83 38 49 17   
10 34 24 105 46 22 41 87 106 3 64   
 
The final model was then run on all these 90%-data-sets. Afterwards, the parameter 
estimates obtained through these runs were compared with the parameter estimates 
from the full input-file. This was done to validate the parameter estimates of the 
model. 
The 10 new models with parameter estimates from the 90%-groups were then used to 
predict the drug concentrations in the corresponding 10%-data-sets. This was done by 
running the models with the commands “MAXEVAL=0” and “POSTHOC” in the 
line $ESTIMATION in the control-file. To gain additional information on the 
predictive power of the models, they were each run on 4 variations of the 10%-data-
sets. The 4 different sets contained, respectively: 1) all the ganciclovir concentration 
measurements per patient, 2) the two first measurements per patient, 3) the first 
measurement per patient, and 4) no measurements per patient. This was done to 
check the predictive performance of the model. 
Finally, the 10 new models with parameter estimates from the 90%-groups were run 
on the full input-file, and the OFV’s from these runs were compared to the OFV from 
the final model on the full input-file. This was done to evaluate the robustness of the 
model [4, 26, 30-32]. 
The equations used to check the performance of the model were as follows: 12) Mean 
prediction error (ME, μg/mL), 13) Mean squared prediction error (MSE, (μg/mL)2), 
14) Root mean squared error (RMSE, μg/mL). The mean prediction error checked the 
Table 2: Patients removed from cross-validation groups 
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bias in the model, the mean squared prediction error and the root mean squared error 
controlled the predictive performance. In addition, Standardized prediction error 
(SPE) was employed to evaluate predictive performance (15) [5, 24]. 
Equation 12:  𝑀𝐸 =
1
𝑛
  𝐶𝑃𝑟𝑒𝑑 − 𝐶𝑂𝑏𝑠  
𝑛
𝑖=1  
Equation 13:  𝑀𝑆𝐸 =
1
𝑛
  𝐶𝑃𝑟𝑒𝑑 − 𝐶𝑂𝑏𝑠  
2𝑛
𝑖=1  
Equation 14:  𝑅𝑀𝑆𝐸 =
1
𝑛
   𝐶𝑃𝑟𝑒𝑑 − 𝐶𝑂𝑏𝑠  2
𝑛
𝑖=1  
Equation 15:  𝑆𝑃𝐸 =
𝐶𝑂𝑏𝑠 −𝐶𝑃𝑟𝑒𝑑
𝑆𝐷𝐶𝑝𝑟𝑒𝑑
 
CObs is the observed concentration, CPred is the predicted concentration, SDCpred is the 
standard deviation of the predicted concentration and n is the total number of 
observations in the validation group. 
2.6.2 Confidence interval 
The Jackknife method was chosen to calculate the confidence interval for the 
parameters in the model. 108 sets of control-files and input-files were created for this, 
and after running them the parameter estimates from each sub-model were gathered. 
Confidence interval, standard error and bias were computed, and the parameter 
estimates were also compared to those from the final model on the full input-file. 
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3. Results 
3.1 Model building results 
The different structural models were compared on the criteria OFV and residual 
variability as shown in table 3. 
As can be seen, more sophisticated models decrease the variability and increase the 
descriptive power up to a certain point. This comes at the expense of increased 
complexity, which results in a larger required computational power and longer run-
time. 
 
Compartment 
model 
ADVAN 
routine 
TRANS 
subroutine 
Objective 
function 
value (OFV) 
Δ OFV 
Residual variability 
Proportional 
(%) 
Additive 
(μg/mL) 
1-
compartment 2 1 324.64 - - 5.33 
1-
compartment 2 2 265.26 59.38 - 3.01 
2-
compartment 4 4 238.64 86 - 2.42 
2-
compartment 4 4 238.64 26.62 31.4 0.413 
3-
compartment 12 4 233.05 5.59 29.8 0.416 
 
  
Table 3: Comparison of structural models by OFV and residual variability 
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In table 4 and 5 the different structural models are compared on their parameter 
estimates. The models show large variations in parameter estimations. Some of these 
variations can be considered to be extreme and non-physiological. 
 
 
Compartment 
model 
ADVAN 
routine 
TRANS 
subroutine 
CL/F 
Q/F 
1 2 
1-
compartment 2 1       
1-
compartment 2 2 11.3     
2-
compartment 4 4 3.54 1.58   
3-
compartment 12 4 6.33 5.71 3.73 
 
     
      Compartment 
model 
V/F 
K KA 
C P1 P2 
1-
compartment       1.99 0.278 
1-
compartment 0.06       0.0154 
2-
compartment 10.9 99.4     2.14*10^21 
3-
compartment 0.1 6130 0.0501   0.0249 
 
Abbreviations: CL=clearance, Q1=intercompartmental clearance for peripheral compartment 1, 
Q2=Intercompartmental clearance for peripheral compartment 2, VC=central volume, VP1= peripheral volume 1, 
VP2=peripheral volume 2, F=bioavailability, K=elimination constant, KA=absorption rate constant. 
 
Various error models were tested during the investigation, both intra-individually and 
inter-individually. An exponential error model gave the best fit for the inter-
individual variances, measured by an improvement of ΔOFV by 0 to 23.1, in addition 
to enhanced stability. The intra-individual error was best explained through a 
combined proportional and additive equation because the model would not run 
successfully with any other equation after advancing to a 2-compartmental model [2, 
25]. 
Table 4: Comparison of different structural models by parameter estimates 
Table 5: Comparison of different structural models by parameter estimates 
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3.1.1 Graphical Comparison of Models 
Patient number 34 (randomization number) was chosen to demonstrate the difference 
between the different structural models in graphical terms. 
 
  
1-compartment, ADVAN2 TRANS1 1-compartment, ADVAN2 TRANS2 
2-compartment, ADVAN4 TRANS4 3-compartment, ADVAN12 TRANS4 
Figure 3: Comparison of different structural models by graphs. Red lines are 
individual predictions, blue lines are population predictions and circles are 
measured drug concentrations. 
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3.2 Analyzing for covariates 
The 2-compartment model with first-order absorption chosen as the structural model 
to further improve with addition of covariates contained the variables clearance 
(CL/F), central volume (V2/F), intercompartmental clearance (Q/F), peripheral 
volume (V3/F), absorption rate constant (KA) and absorption lag time (ALAG). 
These were coded as θ1 to θ6, respectively. 
The starting values for the parameter estimates were all based on data from the 
PV16000 study [25]. The estimates for KA and ALAG were fixed at the values in the 
PV16000 study. 
The parameters were tested in all combinations with the covariates creatinine 
clearance (CRCL), weight (WGT), gender (SEX) and age (AGE), as described in 
section 2.4. 
The covariate SEX was coded as both a linear statement and as an IF/ELSE 
statement. Seeing as none were significantly better than the other, the linear code was 
chosen for simplicity. 
Table six contains the covariates found significant during forward inclusion, while 
table seven shows those that remained significant after backwards deletion. The 
criteria were ΔOFV>3.84 (p<0.05) and ΔOFV>10.9 (p<0.01) for forward inclusion 
and backwards deletion, respectively. 
The original model, without any covariates, had an OFV of 1175.71. After the 
forward inclusion of all significant covariates into the full model, the OFV decreased 
to 1048.03. Ultimately, after the backwards deletion had led to the final model, the 
OFV had risen to 1064.77. This represented a net decrease in OFV of 110.94 since 
the original model, and is highly significant. 
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Covariate Parameter Model OFV ΔOFV P 
CrCl CL TVCL=THETA(1)*(CRCLM**THETA(7)) 1087.40 88.31 p<0.01 
CrCl V3 TVV3=THETA(4)*(CRCLM**THETA(8)) 1083.22 4.18 p<0.05 
WGT CL TVCL=THETA(1)*(CRCLM**THETA(7))*(WGTM**THETA(9)) 1074.00 9.22 p<0.01 
SEX KA KA=THETA(5)*(SEX*(1/THETA(10))) 1059.42 14.58 p<0.01 
SEX ALAG ALAG1=THETA(6)*(SEX*THETA(11)) 1052.40 7.02 p<0.01 
AGE V3 TVV3=THETA(4)*(CRCLM**THETA(8))*(AGE**THETA(12)) 1048.03 4.37 p<0.05 
 
 
3.2.1 Covariate analysis based on visual graphical inspection 
Patient number 97 (randomization number) showed a marked improvement from the 
original model to the final model, as shown in figure 4. The individual and population 
predictions display a greater consistency, and they are better able to “pick up” the 
points representing measured drug concentrations. The graphs are still not optimal, 
showing room for improvement, especially as time progresses. 
 
 
Covariate Parameter Model OFV ΔOFV P 
CrCl CL TVCL=THETA(1)*(CRCLM**THETA(7)) 1157.82 -93.05 p<0.01 
SEX KA KA=THETA(5)*(SEX*(1/THETA(8))) 1113.00 -48.23 p<0.01 
SEX ALAG ALAG1=THETA(6)*(SEX*THETA(9)) 1080.80 -16.03 p<0.01 
Original model Final model 
Table 6: Significant covariates after forward inclusion, equations used and OFV 
Table 7: Significant covariates after backwards deletion, equations used and OFV 
Figure 4: Comparison of original model without covariates and final model with covariates. Red 
lines are individual predictions, blue lines are population predictions and circles are measured 
drug concentrations. 
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The graphs below (figure 5) show three of the patients with the best visual fits in the 
original model (on the left), and three of the patients with the worst visual fits (on the 
right). 
 
  
Figure 5: Three of the patients with the best (on the left) and the worst (on the right) visual 
fits in the original model. Red lines are individual predictions, blue lines are population 
predictions, and circles are measured drug concentrations. 
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Figure 5 shows some of the patients with the best and worst visual fits in the original 
model (left and right, respectively), but this time they are a result of the final model, 
after both forward inclusion and backwards deletion. The improvement in predictive 
power is shown in the graphs below. 
 
 
 
Figure 5: Three of the patients with the best (on the left) and the worst (on the right) visual 
fits in the final model 
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 Goodness of fit plots shown in figures 6-9 below also indicate that the model is fair 
but needs further improvement (which can be readily understood through the OFV). 
The original model has a far wider distribution around the center than the final model. 
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CONC = 1.97 + 0.384 PRED, R-Sq = 8.5%
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CONC = 0.767 + 0.854 PRED, R-Sq = 16.9%
 
Figure 6: GOF plot of concentration vs. population prediction for original model. The 
dotted line is the union, the whole line is the regression line. 
Figure 7: GOF plot of concentration vs. population prediction for final model including 
covariates. The dotted line is the union, the whole line is the regression line. 
 42 
In addition to the more centered “look” of the plot for the final model (figure 7), the 
minimum/maximum WRES range has decreased from -2.42/13.50 of the original 
model (figure 8) to -2.22/9.69 of the final model (figure 9). 
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Figure 8: GOF plot of weighted residual vs. population prediction for original model 
Figure 9: GOF plot of weighted residual vs. population prediction for final model 
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3.3 The final model for valganciclovir 
We concluded that a 2-compartment model with first-order absorption best described 
the data at hand. The estimation method employed was the first-order conditional 
estimate (FOCE). 
The inter-individual error was modeled with an exponential function, while a 
combined proportional and additive error-model best described the residual 
variability. 
The model in table 8 below was the final model used. It also contains all starting 
estimates for THETA, OMEGA and SIGMA. These are, respectively, parameter 
estimates, inter-individual error variance and intra-individual error variance. 
 
 
$PROB final model, faar vi se hvordan det gaar 
 
$DATA alleValPOalder-1.txt 
 
$INPUT ID AMT RATE DATE=DROP TIME CRCL WGT CONC=DV MDV 
DOSE=DROP SEX DAY=DROP PASN=DROP AGE 
 
$SUBROUTINE ADVAN4 TRANS4 
 
$PK 
CRCLM=CRCL/57.65 ; median 
WGTM=WGT/66 ; median 
 
TVCL=THETA(1)*(CRCLM**THETA(7)) 
CL=TVCL*EXP(ETA(1)) 
TVV2=THETA(2) 
V2=TVV2*EXP(ETA(2)) 
TVQ=THETA(3) 
Q=TVQ*EXP(ETA(4)) 
TVV3=THETA(4) 
V3=TVV3*EXP(ETA(3)) 
KA=THETA(5)*(SEX*(1/THETA(8))) 
ALAG1=THETA(6)*(SEX*THETA(9)) 
 
Table 8: The final model for valganciclovir 
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; THE FOLLOWING ARE REQUIRED BY PREDPP 
 
K=CL/V2 
K23=Q/V2 
K32=Q/V3 
S2=V2 
S3=V3 
 
$ERROR 
IPRED=F 
Y=F+F*ERR(1)+ERR(2) 
 
$THETA 
(0, 12, 50) 
(0, 59.4, 100) 
(0, 7.21, 100) 
(0, 304, 400) 
(0, 0.287) FIXED 
(0, 0.661) FIXED 
1.12 
3.55 
4.77 
 
$OMEGA 
0.329 4.11 3.42 0.533 
 
$SIGMA 
0.181 0.354 
 
$ESTIMATION SIG=3 METHOD=1 INTER MAXEVAL=2000 PRINT=0 
POSTHOC NOABORT 
 
$TABLE ID DV TIME 
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID KA K AMT TIME IPRED V2 V3 
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
 
The graphs in figures 10 and 11 below show the Goodness of Fit scatterplots of 
CONC/PRED and CONC/IPRED for the final model. There is considerable spread in 
the population estimate, as well as some bias towards under-prediction. This can be 
seen in figure 10 because the bulk of the measurements lie under the line of union, 
while there are quite a few measurements in the left part of the plot high above the 
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line. The individual prediction however shows an acceptable precision of prediction. 
In figure 11 the measurements are more evenly distributed around the union, and the 
high concentrations are relatively well predicted, and thereby centered along the line. 
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Figure 10: Goodness of fit plot of measurements vs. population predictions for the final model. 
The dotted line is the union, the whole line is the regression line. 
Figure 11: Goodness of fit plot of measurements vs. individual predictions for the final model. 
The dotted line is the union, the whole line is the regression line. 
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As can be seen from the plot of WRES vs. TIME (figure 12), there is a slight trend 
towards positive residuals. This also seems to first decrease somewhat with time, but 
then increase again after about 25 days. 
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The WRES vs. PRED plot (appendix 7.3.5) shows a very large positive WRES bias, 
which seems to decrease somewhat with increasing PRED values. 
This bias is maintained in the WRES vs. IPRE plot (appendix 7.3.6), but here it is 
more spread out. Apart from this, the weighted residuals are fairly well centered on 
the zero-line, with a slight majority of the bulk on the negative side. 
  
Figure 12: Plot of weighted residuals vs. time for the final model 
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3.4 Validating the final model 
3.4.1 Internal validation 
 
The plots below (figure 13) illustrate the parameter estimates from each of the ten 
90%-groups. Each plot shows that between three and seven estimates are more than 
two standard deviations away from the full input-file estimates. 
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Figure 13: Parameter estimates from 90%-groups compared to full input-file. The green 
lines are one standard deviation away from the estimate of the final model on the full input-
file, while the red lines are two standard deviations away. 
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3.4.2 Examining the predictive performance of the population 
model 
Table 9 displays the prediction errors of the final model when run on the full data-set, 
with only the first and second observation, only the first observation and finally no 
drug concentration measurements at all. 
Mean prediction error is a measure of bias, and the table shows that the model 
slightly under-predicts the concentrations. 
Mean squared prediction error and Root mean squared error both ascertain the models 
precision in its predictions. It is apparent that the input-file with all measurements 
included gives the best predictions, while they become incrementally worse as the 
number of observations decreases. 
The Average standardized prediction error was fairly close to zero on all input-files, 
which strengthens the validity of the models fit to the data. The 95% CI also 
contained zero for all input-files but the one without any observations. 
 
 
 
 
 
 
All One & Two None Only One 
      
Mean 
Prediction 
Error 
(ME) 
Mean -0.15 -0.29 -0.36 -0.28 
SD 1.58 1.97 2.80 2.15 
95% CI min. -0.27 -0.44 -0.57 -0.45 
95% CI 
max. -0.03 -0.14 -0.14 -0.12 
 
     Mean 
Squared 
Prediction 
Error 
(MSE) 
Mean 2.51 3.95 7.94 4.68 
SD 6.21 12.83 25.71 14.31 
95% CI min. 2.39 3.79 7.72 4.52 
95% CI 
max. 2.63 4.10 8.15 4.85 
 
     
Root Mean 
Squared 
Error 
(RMSE) 
Mean 1.06 1.25 1.80 1.38 
SD 1.18 1.55 2.17 1.67 
95% CI min. 0.94 1.10 1.59 1.22 
95% CI 
max. 1.18 1.40 2.02 1.55 
Table 9: Validation of final model by statistical comparison of predictive error 
when measurements are excluded from the input-file 
 49 
 
     Average 
Standardized 
Prediction 
Error 
(SPE) 
Mean -0.06 -0.13 -0.24 -0.13 
SD 0.64 0.87 1.85 1.00 
95% CI min. -0.18 -0.28 -0.45 -0.30 
95% CI 
max. 0.06 0.02 -0.02 0.03 
ME and RMSE have the unit μg/mL, while RMSE has the unit (μg/mL)2 
 
Table 10 contains OFVs for the 90%-groups compared to the OFV from the full 
input-file. All the OFVs were centered very well on the OFV from the full input-file, 
and none deviated more than 2.39 away from it. This is well inside the cut-off value 
of 3.84 for a 95% CI, and is highly significant. This indicates that the model is quite 
robust. 
 
OFV Value 
Final model 1362.63 
Mean Minimum Subgroups 
Fixed 
parameter 
values from 
included 
subsets 
(90%) on 
full input 
file 
1 1362.74 
2 1363.01 1362.998 1362.11 
3 1363.32 
Median Maximum 4 1362.11 
5 1363.00 
6 1365.02 1362.87 1365.02 
7 1362.71 
Standard 
deviation 
Standard 
error of 
mean 
8 1362.16 
9 1363.24 
10 1362.67 0.81641221 0.25817221 
 
 
3.4.3 Confidence interval of population parameters 
Table 11 contains the results from the Jackknife method. 
As can be seen from the results in the table below, the Jackknife method showed that 
no single patient had any significant influence on the parameter estimates gained 
through use of the final model. 
Table 10: Validation of final model by statistical comparison of OFVs when is 
stabilized on 90% of the population, then run on the full input-file 
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PK Parameters Mean Median SD 
 Clearance (CL) 12.013 12.000 0.048 
 Central Volume (V2) 60.206 59.400 2.761 
 Intercompartmental Clearance (Q) 7.199 7.210 0.199 
 Peripheral Volume (V3) 307.093 304.000 7.794 
 
     
PK Parameters Minimum Maximum 
95% CI 
min. 
95% CI 
max. 
Clearance (CL) 12.000 12.300 12.004 12.022 
Central Volume (V2) 58.400 79.800 59.686 60.727 
Intercompartmental Clearance (Q) 5.540 7.940 7.162 7.237 
Peripheral Volume (V3) 273.000 346.000 305.623 308.562 
 
  
Table 11: Validation of final model by statistical comparison of parameter 
estimates after use of the Jackknife method 
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4. Discussion 
4.1 Model building 
Building the model was a challenging task. Searching for literature on population 
modeling of valganciclovir divulged disappointingly little. Very few studies on 
similar problems had been performed, and none on patients treated for active CMV-
disease as in the VICTOR trial. There did however turn up one study that was very 
similar to ours during the last weeks of the thesis-writing, by Perrottet et al. [15], but 
it was not available during the development phase of the model. Wiltshire et al. had 
conducted the PV16000 study which was available for reference during the building 
of our model, and it was used as a template and guide in this process. The main 
difference between PV16000 and VICTOR was that PV16000 was conducted as a 
prophylactic study, where patients were given valganciclovir immediately after 
transplantation to prevent viral replication. VICTOR was a treatment study, where 
only transplant recipients with active CMV-disease were given valganciclovir. In 
addition, VICTOR had a secondary goal which was the investigation for a correlation 
between ganciclovir plasma concentration, viremia concentration and adverse effects. 
Both the PREDPP routines used, as well as the initial parameter estimates, were 
useful in choosing a place to start. 
It was also noted that both Perrottet et al. and Wiltshire et al. had chosen to employ 
the 2-compartment set-up with first-order absorption. This lends strength to the 
argument that the 2-compartment is the optimal choice [13, 15]. 
Model building was a time consuming process, with much trial and error. The 
challenges lay mainly in getting the models to run, and getting the parameters stable. 
In the end, not many different models were tested before a two-compartment model 
was chosen. Only first-order absorption was tested, based on data gathered in a 
previous study [25]. 
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It was decided that a 2-compartment model with first-order absorption was a 
reasonable assumption. This was based upon the OFV which was far better than the 
1-compartment models, the better stability and shorter run-time than the 3-
compartment model and the visual inspection of the plots. It also seemed appropriate 
considering the chemical and pharmacokinetic profile of valganciclovir.  
In addition, other approaches to structural models would be tested and compared to 
the 2-compartmental model with first-order absorption. 
The work of developing a model was dependent on a good input-file, the creation of 
which was a time-consuming task. The finished Excel worksheet contained 14 
columns and 7622 rows of data. 
The control-files were designed based on earlier studies by Wiltshire et al. [13] as 
well as Trúc Vân Lê [33]. The NONMEM guides [22] were also essential to the 
construction of different models. 
During the initial development and the search for the optimal type of structural model 
to build our own model on, we used a minimal data-set with 11 patients to get a feel 
for the different models. We then increased the number of patients to 30 to see how 
this affected the initial assumptions on differences between models. After running 
some further tests on this set, we finally included all patients in the input-file. 
After having built the full data-set, some of the first runs showed that a few of the 
more extreme observations caused stability problems. We therefore trimmed the data-
set and used this new version alongside the full version during forward inclusion and 
backwards deletion. After that we discarded the trimmed set and only used the full 
set. No data-points were excluded in the final testing of the model, seeing as we had 
no rational for judging them as sampling- or calculation-errors. 
4.1.1 1-compartment, first-order absorption 
This model was written with ADVAN2 and two different subroutines: TRANS1 and 
TRANS2. The different numbered ADVANs instruct NONMEM as to how many 
compartments the model should have, and whether or not it has an absorption 
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compartment. The TRANS subroutines instruct NONMEM which basic PK 
parameters the user will supply starting estimates for. Here TRANS1 means the user 
must supply an estimate of the rate constant of elimination (K), while in TRANS2 he 
must supply estimates of clearance (CL) and volume of distribution (V). 
TRANS1: This model showed a very poor fit to the data. The plots had few curves, 
mostly hard edges, and a distinctly unnatural look. The elimination was also much 
too fast, as seen by how the concentration-curve fell vertically to zero immediately 
after the dosage decreased or ceased. The plots of observed/predicted vs. time also 
showed a severe bias of firstly under-prediction which then turned to over-prediction 
with time. The OFV was 324.64. This model was discarded because of its obvious 
uselessness. 
TRANS2: This approach displayed a much smoother attempt at plotting the 
predictions. There was still a certain amount of under-prediction, but far less than 
with TRANS1. The model was also much more consistent in its estimations. 
Particularly the individual predictions were showing an improved fit to the measured 
data. The OFV of 265.26 was also far superior to the TRANS1 model. 
Clearance (CL/F) was here estimated at 11.3 L/h and central volume (V2/F) at 0.06 
L. Not ideal by any means. 
4.1.2 2-compartment, first-order absorption 
The control-file here utilized the ADVAN4 routine with the TRANS4 subroutine. 
ADVAN4 means the model is 2-compartment with first-order absorption, and 
TRANS4 means here that the user must supply clearance (CL), central volume (V2), 
intercompartmental clearance (Q), peripheral volume (V3) and absorption rate 
constant (KA). Visually there was not much improvement to the plots as compared to 
the 1-compartment model with TRANS2. The OFV though did sink to 238.64, a 
betterment of Δ26.62. The under-prediction also persisted as in the prior attempts. At 
this point in the development, the model experienced serious problems with stability. 
After some research and experimentation, a change of the intra-individual error 
model from additive to combined proportional and additive proved to be the solution. 
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This error model was then kept as the standard in the models further development. 
The estimate of clearance (CL/F) was now 3.54 L/h and central volume (V2/F) was 
10.9 L, with a peripheral volume (V3/F) of 99.4 L and an intercompartmental 
clearance (Q/F) of 1.58 L/h. This seemed more plausible. 
4.1.3 3-compartment, first-order absorption 
This step in the building phase used the ADVAN12 routine with the TRANS4 
subroutine. ADVAN12 means it is a 3-compartment model with first-order 
absorption. TRANS4 means here the user must input estimates for the parameters 
clearance (CL), central volume (V2), intercompartmental clearance between central 
and peripheral 1 (Q3), peripheral 1 volume (V3), intercompartmental clearance 
between central and peripheral 2 (Q4), peripheral 2 volume (V4) and absorption 
constant (KA). There was some visual change in the plots, a more rapidly decreasing 
curve, but not by much. The under-prediction stayed the same though. The slight 
improvement was noticeable in the OFV, as it sank by 5.59, to 233.05 points. While 
this was statistically significant, there arose stability problems which kept returning. 
The parameter estimations in this model: clearance (CL/F) was 6.33 L/h, 
intercompartmental clearance one (Q1/F) and two (Q2/F) were 5.71 L/h and 3.73 L/h 
respectively, central volume (V2/F) was 0.1 L, and peripheral volumes one (V3/F) 
and two (V4/F) were 6130 L and 0.05 L respectively. The volumes in particular were 
improbable. 
This, in addition to the increased complexity, longer run-time and minimal 
improvement in prediction- and goodness of fit-plots, led us to decide not to continue 
development of this file. 
The 2-compartmental model with first-order absorption was chosen for further 
development. It showed far superior OFV and visual graphical fit over the two 1-
compartmental models, and a superior stability as well as run-time over the 3-
compartmental model. In addition it complied with previous findings [13]. 
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4.2 Analyzing for covariates 
During the forward inclusion we found it somewhat strange that neither weight nor 
sex had any significant influence on either central or peripheral volume. This was 
surprising, as we expected gender-based divergences to stem from differences in 
liquids and fat. The fact that gender had such a strong effect on absorption constant 
(KA) and absorption time lag (ALAG) was also unexpected. This might warrant 
further investigation, either with a different kind of data set or with different kind of 
coding. 
The estimation-values for KA and ALAG were fixed at the values from the PV16000 
study. We chose to do this because all our drug measurements were trough-
measurements. This did not enable us to estimate these parameters with sufficient 
accuracy to establish our own estimates. 
When preparing to do the backwards deletion, we chose the very strict criterion of 
ΔOFV > 10.9, giving p<0.01. We did this to be quite sure that the covariates chosen 
were indeed significant, but in hindsight this was perhaps too stringent. P<0.05 would 
still have been significant, and would have let some more covariates be included in 
the model. This could possibly have improved the predictive capability of the model. 
During the writing of the input-file the time for administration of morning dose and 
taking of blood samples was set to a uniform 08:00, and 08:20 when there had been 
taken a sample. The administration of the evening dose was set to 20:00. 
Later on, during the writing of the thesis, information was found that detailed 
deviations from the planned administration and sampling schedule. Some tests were 
run on a few patients that were affected by this, to ascertain if it would have any 
serious impact on the results of the final model, and the validity of it. These tests 
showed a negligible effect on the models predictions after the inclusion of this data. 
Nevertheless, it should be kept in mind that the inclusion of these corrections on the 
data of the patients in question could prove significant for the predictive precision of 
the population model. 
Because all the measurements were trough-concentrations, we were not able to 
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estimate absorption lag time (ALAG) nor the absorption constant (KA) to any 
reasonably stable degree. Should this additional time data prove diverse enough, it 
might allow the estimation of KA and ALAG from the data at hand. This could 
improve the models predictive power. 
During the decision-making process where factors were evaluated for inclusion in the 
testing for covariates, time after transplant was considered not to be a probable 
candidate. During the finishing work on the thesis, however, it was discovered that 
time after transplant was included in some population models on ciclosporin A were 
sampling had been done on different occasions [33]. Considering that our data had 
been sampled over a period of 50 days, and that patients had been included in the 
study on varying times after receiving transplants, the decision about testing time 
after transplant was reconsidered. We now believe it merits testing for significance as 
a covariate in the model, and that this should be done in a possible further refinement 
of this model. 
Gender was modeled with both linear equations and IF/ELSE statements. This was 
done because some literature and previous studies [23, 33] had coded gender in that 
way. This did however not significantly improve our model, and the linear function 
was therefore chosen. This made the model slightly simpler by reducing the number 
of thetas by 1-2, depending on equation. 
Comparing the original model and the final model shows that inclusion of covariates 
made a definite improvement. Especially in the individual predictions a much better 
fit to the data at hand can be observed. The population predictions were not that much 
better, compared to the individual predictions. The under-prediction was also still 
quite evident. The refinement of the entered time-data might be worth testing to see if 
it would mitigate the state of the model, as well as the reevaluation of certain factors 
regarding possible inclusion as covariates. 
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4.3 The final model for valganciclovir 
The model chosen as original model after testing of different possibilities was the 2-
compartment model with first-order absorption. The plots described the data 
reasonably well compared to the other models tested. The stability was also adequate, 
particularly after adjustment of the residual error function. In addition the run-time 
was short, which is not only good during the building and validation of a population 
model, but also later on should it be chosen for use in a clinical setting. While the 2-
compartment model was not as good as the 3-compartment when compared on OFV, 
it sported superior run-time, simplicity and most important, stability. 
As has been mentioned earlier, the final model shows a certain positive bias in the 
plot of its residuals. One can also see that there is a tendency towards a decrease in 
residuals with higher concentrations, although slight. This might indicate a problem 
with either predictions or measurements at lower concentrations, or simply a result of 
the fact that there are more low concentration measurements than there are high. 
The plot of weighted residuals vs. time displays an increase in the spread of residuals 
from around 600 hours (25 days). This coincides roughly with the end of the 
induction period and the beginning of the maintenance period (day 21). Whether or 
not this is a coincidence, and if there are any other factors that might be responsible 
for this, might merit further investigation. 
Under-prediction has plagued our model since the very beginning, and we were not 
able to eliminate it to a satisfying degree. Exactly why this persists remains therefore 
undetermined, but may be correlated with the high estimations of V2/F and V3/F. It 
may be an error stemming from divergences in measurement or protocol deviations. 
It could also be non-compliance on the patient’s part. Lastly, it may be factors we did 
not consider, and that would have had an influence on our model. 
The data-set contained a number of measurements that seemed strangely high 
compared to different measurements in the same patient. Inter-occasional variability 
could of course be responsible for this, but it might be advisable to investigate if these 
concentrations are real or if they are erroneous. Should the latter be the case it could 
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possibly mitigate some of the problems the model has with large residuals. Then 
again, many of these measurements were predicted with a high enough degree of 
accuracy. 
The goodness of fit plot for concentration vs. population prediction (figure 10) shows 
a drastic amount of spread. It also shows once more the under-prediction, as well as 
the measurements that diverge widely from the others in the population. 
The plot for concentration vs. individual prediction (figure 11) is much more 
accurate. It shows a large degree of consistency, that is particularly impressing when 
compared to the previous plot. It also shows that most of the drug concentration 
measurements in the high end of the scale can be predicted to a certain degree. This 
supports the view that these are real measurements, not errors. 
4.4 Validating the Model 
When validating a model one is basically checking how good it really is. Taking off 
the training-wheels, so to speak. A model may be developed which looks very good. 
It can have a high predictive precision, be simple, fast and stable, and yet still come 
short at the validation step. If it is too fragile to cope with changes in the data-
material, it is not a very versatile model. In some cases, where the model only seeks 
to explain the data in a given set, this may not be a problem. But when one designs a 
model to make predictions on a population beyond the available data, one must make 
sure it makes valid predictions for said population. 
There are many different methods and approaches for validation, and since there are 
none that are clearly superior in every case, a researcher is at the mercy of his own 
decision. There may also be situations where one model has clear advantages over 
another [4, 5]. 
Validating a model can be defined as testing to see if a model developed on a set of 
data called developmental data manages to accurately predict the observations made 
in a set of data called the validation data. 
Whether or not a model is judged valid depends largely on the purpose of the model, 
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meaning that models are seldom good all-round solutions, but rather developed 
specifically for a single task. There is no correct answer to the question: “what is the 
right model?”. Neither is there a single correct way to develop aforesaid model, nor to 
test it. Therefore personal opinion is a deciding factor when it comes to both the 
developing and testing of a model. As can be easily derived from this, there does not 
exist any consensus at the time of writing regarding what is the single best approach 
to validation. There are different validation methods, and some may be more prudent 
to use than others when it comes down to each single model. There is simply too 
much complexity possible in models for any one method to be able to reliably 
validate them all [4]. 
I will briefly mention some types of validation. 
 
External validation is when one develops a model on a certain data-set, and then 
afterwards validates the model on a different but relevant data-set. This is the most 
rigorous method for testing a model. 
 
Internal validation is when only one set of data is being used for both development 
and validation of the model. This term contains some different methods and 
techniques. 
 
Data splitting is when one splits the data set in two parts. One is used for model 
building, and the second is used for validation. It is often recommended to make a 2-1 
split. Two thirds are used for building, one third for testing. 
 
Cross-validation is essentially a repeated data-splitting process. The results from each 
data-split give a prediction-error estimate, and these are averaged across all the 
repeats. The splits can be done randomly or not, and with different organizational 
approaches. A common method which will be used in this thesis is the K-fold cross-
validation. The data is split into K parts. Then the model is fitted to K-1 of the parts, 
before it is validated on the last part. This is done K times, and the results are then 
averaged. One of the benefits is a reduced variability because one does not rely on a 
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single sample split [27, 28]. 
 
Bootstrapping is a form of resampling. After having taken a sample of size N from a 
population, one then repeatedly takes samples of size N from this first sample, but 
with replacement. Since the first sample is representative of the population, this will 
give the effect of having taken many samples from the population instead of just one. 
One can then calculate for instance a parameter in each second sample, and get a 
mean, variance and interval from looking at them all [28, 34]. 
 
Jackknife is a method for inferring the bias and the standard error of a particular 
statistic, for instance a parameter in a PK model. It is a resampling technique quite 
similar to bootstrapping, and basically consists of re-computing the statistic in 
question a number of times equal to the number of observations in the data set. Each 
time, though, one removes a different observation. From this new set of estimates one 
can then calculate bias and standard error for the parameter derived from the original 
full data set. Jackknife is not as widely applicable as the Bootstrap, but requires 
mostly less computational power. While the results gained from the two methods are 
often similar, the numbers yielded will still usually be different to varying degrees 
[28, 31]. 
In this thesis the decision to use a K-fold cross-validation and the jackknife method 
was based on recommendations from the Food and Drug Administration (FDA), as 
well as the work done in the thesis by Trúc Vân Lê [4, 33]. 
The results from the validation of the final model showed that OFV remained almost 
constant across the variations in sub-population groups. This indicates great 
robustness in the model. On the other hand, the parameter estimates from the sub-
population groups varied widely. This might indicate that the original population was 
on the verge of how small it could be while still having enough power for predictive 
significance. When we further decreased the number of individuals in a group, it may 
have brought it below the limit necessary to give stable parameter estimates. This 
might have been circumvented by increasing the number of folds in the cross-
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validation to for instance K-20. 
The wide variations in estimates could of course also be indicative of a lack of 
stability across differing data-sets, or possibly hidden covariates. 
The parameter estimates of the final model were quite acceptable for clearance (CL/F 
= 12.00 L/h) and intercompartmental clearance (Q/F = 7.21 L/h). The central volume 
(V2/F = 59.40 L) and peripheral volume (V3/F = 304.00 L) estimates were however 
somewhat unexpected. The previous study by Wiltshire et al. [25] had found 18.5 L 
and 44.4 L respectively, and the study by Perrottet et al. reported 28 L and 19.5 L 
respectively. While these showed some variation, our estimates were still far higher, 
particularly for the peripheral volume (V3), indicating a reason for the under-
prediction by the model. 
When performing the cross-validation on the four different 10%-groups, we observed 
that the sets with all the data points gave the best predictions, and that through the 
sets with two data points and one data point the predictions became gradually worse, 
ending up at the worst predictions on the data-set with no data points. This was what 
we had expected. 
It should also be mentioned that the first data point used in set two and three was 
from day 3 in the study. This was done because some patients had minute 
concentrations measured in their samples on day 0. They should not have had any 
drug in their blood at that time, and it might indicate that they already were on the 
drug at the start of the study, or that there had been deviations from the administration 
and measurement schedule. 
The Jackknife method used to calculate the 95% confidence interval required the 
tedious creation of 108 control-files and 108 input-files. It was nevertheless chosen 
above the Bootstrap method because it requires less computational power. 
The confidence intervals gained display a sufficient lack of variation, and show that 
no single patient had any significant influence on the parameter estimates. 
The validation showed both the apparent robustness of the model through the 
stableness of the OFVs after the cross-validation, and the apparent instability after the 
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comparison of the parameter estimates of the 10 sub-groups. It also showed that the 
model requires at least a few data points to give any meaningful predictions, and that 
although the population predictions are not particularly impressive, the individual 
predictions still are quite accurate. 
Even so, there is much room for improvement. There is the possibility of additional 
significant covariates, and there are measurements that seem strange compared to the 
others. The data-set might need to be embellished with more detailed time-data, and 
the residuals point towards decreased predictive accuracy with time as well as with 
low concentrations. All in all, the final model is a good start, but it needs further 
development. 
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5. Conclusions 
A pharmacokinetic population model was developed by means of the nonlinear 
mixed effects modeling computer program NONMEM for ganciclovir after 
administration of the prodrug valganciclovir in solid organ transplant recipient 
patients. After further refinement and combination with a model for CMV, this model 
may be of clinical use in devising dosage regimes as well as investigating 
associations with therapeutic effect and adverse events. This is the overall goal of 
developing the population pharmacokinetic model in this thesis. 
A 2-compartment model with first-order absorption, combined with the covariates 
creatinine clearance on clearance and gender on absorption rate constant and 
absorption lag time, was found to be the best model. 
The validation of the model showed that it was apparently robust, but at the same 
time, however, the parameter estimates produced differed greatly on the same varied 
population-base. This indicates that the model has trouble dealing with different 
populations. 
Nevertheless, the model delivered good individual predictions for all population sets, 
provided it had at least a single drug-concentration measurement per individual to 
work with. 
The model shows potential for further refinement, but manages regardless to fulfill 
the goals as set down for this thesis. 
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7. Appendix 
7.1 Cockcroft-Gault equation 
𝐺𝐹𝑅 =
 140 − 𝑎𝑔𝑒 𝑖𝑛 𝑦𝑒𝑎𝑟𝑠 × 𝑤𝑒𝑖𝑔𝑕𝑡 𝑖𝑛 𝑘𝑔𝑠
72 × 𝑆𝑒𝑟𝑢𝑚 𝑐𝑟𝑒𝑎𝑡𝑖𝑛𝑖𝑛𝑒 𝑖𝑛 
𝑚𝑔
𝑑𝐿 
× 0.85 𝑓𝑜𝑟 𝑤𝑜𝑚𝑒𝑛 
7.2 Partial input-file for NONMEM 
#ID AMT RATE DATE TIME CRCL WGT 
CONC
=DV MDV DOSE SEX DAY PASN AGE 
1 0 0 
8/1/2
006 08:00 84.53 89 0 0 900 2 0 6 40 
1 900 0 
8/1/2
006 20:00 84.53 89 0 1 900 2 0 6 40 
1 900 0 
8/2/2
006 08:00 84.53 89 0 1 900 2 1 6 40 
1 900 0 
8/2/2
006 20:00 84.53 89 0 1 900 2 1 6 40 
1 900 0 
8/3/2
006 08:00 84.53 89 0 1 900 2 2 6 40 
1 900 0 
8/3/2
006 20:00 84.53 89 0 1 900 2 2 6 40 
1 0 0 
8/4/2
006 08:00 84.53 89 2.23 0 900 2 3 6 40 
1 900 0 
8/4/2
006 08:20 82.63 89 0 1 900 2 3 6 40 
1 900 0 
8/4/2
006 20:00 82.63 89 0 1 900 2 3 6 40 
1 900 0 
8/5/2
006 08:00 82.63 89 0 1 900 2 4 6 40 
1 900 0 
8/5/2
006 20:00 82.63 89 0 1 900 2 4 6 40 
1 900 0 
8/6/2
006 08:00 82.63 89 0 1 900 2 5 6 40 
1 900 0 
8/6/2
006 20:00 82.63 89 0 1 900 2 5 6 40 
1 900 0 
8/7/2
006 08:00 82.63 89 0 1 900 2 6 6 40 
1 900 0 
8/7/2
006 20:00 82.63 89 0 1 900 2 6 6 40 
1 0 0 
8/8/2
006 08:00 82.63 89 0.68 0 900 2 7 6 40 
1 900 0 8/8/2 08:20 76.61 89 0 1 900 2 7 6 40 
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006 
1 900 0 
8/8/2
006 20:00 76.61 89 0 1 900 2 7 6 40 
1 900 0 
8/9/2
006 08:00 76.61 89 0 1 900 2 8 6 40 
1 900 0 
8/9/2
006 20:00 76.61 89 0 1 900 2 8 6 40 
1 900 0 
8/10/
2006 08:00 76.61 89 0 1 900 2 9 6 40 
1 900 0 
8/10/
2006 20:00 76.61 89 0 1 900 2 9 6 40 
1 0 0 
8/11/
2006 08:00 76.61 89 2.03 0 900 2 10 6 40 
1 900 0 
8/11/
2006 08:20 83.58 89 0 1 900 2 10 6 40 
1 900 0 
8/11/
2006 20:00 83.58 89 0 1 900 2 10 6 40 
1 900 0 
8/12/
2006 08:00 83.58 89 0 1 900 2 11 6 40 
1 900 0 
8/12/
2006 20:00 83.58 89 0 1 900 2 11 6 40 
1 900 0 
8/13/
2006 08:00 83.58 89 0 1 900 2 12 6 40 
1 900 0 
8/13/
2006 20:00 83.58 89 0 1 900 2 12 6 40 
1 900 0 
8/14/
2006 08:00 83.58 89 0 1 900 2 13 6 40 
1 900 0 
8/14/
2006 20:00 83.58 89 0 1 900 2 13 6 40 
1 0 0 
8/15/
2006 08:00 83.58 89 2.99 0 900 2 14 6 40 
1 900 0 
8/15/
2006 08:20 84.53 89 0 1 900 2 14 6 40 
1 900 0 
8/15/
2006 20:00 84.53 89 0 1 900 2 14 6 40 
1 900 0 
8/16/
2006 08:00 84.53 89 0 1 900 2 15 6 40 
1 900 0 
8/16/
2006 20:00 84.53 89 0 1 900 2 15 6 40 
1 900 0 
8/17/
2006 08:00 84.53 89 0 1 900 2 16 6 40 
1 900 0 
8/17/
2006 20:00 84.53 89 0 1 900 2 16 6 40 
1 0 0 
8/18/
2006 08:00 84.53 89 5.32 0 900 2 17 6 40 
1 900 0 
8/18/
2006 08:20 85.48 89 0 1 900 2 17 6 40 
1 900 0 
8/18/
2006 20:00 85.48 89 0 1 900 2 17 6 40 
1 900 0 
8/19/
2006 08:00 85.48 89 0 1 900 2 18 6 40 
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1 900 0 
8/19/
2006 20:00 85.48 89 0 1 900 2 18 6 40 
1 900 0 
8/20/
2006 08:00 85.48 89 0 1 900 2 19 6 40 
1 900 0 
8/20/
2006 20:00 85.48 89 0 1 900 2 19 6 40 
1 900 0 
8/21/
2006 08:00 85.48 89 0 1 900 2 20 6 40 
1 900 0 
8/21/
2006 20:00 85.48 89 0 1 900 2 20 6 40 
1 0 0 
8/22/
2006 08:00 85.48 89 6.98 0 900 2 21 6 40 
1 900 0 
8/22/
2006 08:20 78.36 89 0 1 900 2 21 6 40 
1 900 0 
8/23/
2006 08:00 78.36 89 0 1 900 2 22 6 40 
1 900 0 
8/24/
2006 08:00 78.36 89 0 1 900 2 23 6 40 
1 900 0 
8/25/
2006 08:00 78.36 89 0 1 900 2 24 6 40 
1 900 0 
8/26/
2006 08:00 78.36 89 0 1 900 2 25 6 40 
1 900 0 
8/27/
2006 08:00 78.36 89 0 1 900 2 26 6 40 
1 900 0 
8/28/
2006 08:00 78.36 89 0 1 900 2 27 6 40 
1 0 0 
8/29/
2006 08:00 78.36 89 4.89 0 900 2 28 6 40 
1 900 0 
8/29/
2006 08:20 77.48 89 0 1 900 2 28 6 40 
1 900 0 
8/30/
2006 08:00 77.48 89 0 1 900 2 29 6 40 
1 900 0 
8/31/
2006 08:00 77.48 89 0 1 900 2 30 6 40 
1 900 0 
9/1/2
006 08:00 77.48 89 0 1 900 2 31 6 40 
1 900 0 
9/2/2
006 08:00 77.48 89 0 1 900 2 32 6 40 
1 900 0 
9/3/2
006 08:00 77.48 89 0 1 900 2 33 6 40 
1 900 0 
9/4/2
006 08:00 77.48 89 0 1 900 2 34 6 40 
1 0 0 
9/5/2
006 08:00 78.36 89 5.44 0 900 2 35 6 40 
1 900 0 
9/5/2
006 08:20 78.36 89 0 1 900 2 35 6 40 
1 900 0 
9/6/2
006 08:00 78.36 89 0 1 900 2 36 6 40 
1 900 0 
9/7/2
006 08:00 78.36 89 0 1 900 2 37 6 40 
1 900 0 
9/8/2
006 08:00 78.36 89 0 1 900 2 38 6 40 
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1 900 0 
9/9/2
006 08:00 78.36 89 0 1 900 2 39 6 40 
1 900 0 
9/10/
2006 08:00 78.36 89 0 1 900 2 40 6 40 
1 900 0 
9/11/
2006 08:00 78.36 89 0 1 900 2 41 6 40 
1 0 0 
9/12/
2006 08:00 78.36 89 4.25 0 900 2 42 6 40 
1 900 0 
9/12/
2006 08:20 80.1 89 0 1 900 2 42 6 40 
1 900 0 
9/13/
2006 08:00 80.1 89 0 1 900 2 43 6 40 
1 900 0 
9/14/
2006 08:00 80.1 89 0 1 900 2 44 6 40 
1 900 0 
9/15/
2006 08:00 80.1 89 0 1 900 2 45 6 40 
1 900 0 
9/16/
2006 08:00 80.1 89 0 1 900 2 46 6 40 
1 900 0 
9/17/
2006 08:00 80.1 89 0 1 900 2 47 6 40 
1 900 0 
9/18/
2006 08:00 80.1 89 0 1 900 2 48 6 40 
1 0 0 
9/19/
2006 08:00 80.1 89 3.71 0 900 2 49 6 40 
1 900 0 
9/19/
2006 08:20 80.1 89 0 1 900 2 49 6 40 
 
 
7.3 Control files for NONMEM 
7.3.1 1-compartment with first-order absorption 
Trans 1: 
$PROB En-kompartment med absorpsjon 
 
$DATA test7.txt 
 
$INPUT ID AMT RATE DATE=DROP TIME CRCL WGT CONC=DV MDV 
DOSE SEX=DROP DAY=DROP PASN=DROP 
 
$SUBROUTINE ADVAN2 TRANS1 
 
$PK 
K=THETA(1)*EXP(ETA(1)) 
KA=THETA(2)*EXP(ETA(2)) 
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$ERROR 
IPRED=F 
Y=F+ERR(1) 
 
$THETA 
(0, 0.5, 2) 
(0, 0.4, 2) 
 
$OMEGA 
0.00002 0.01 
 
$SIGMA 
3 
 
$ESTIMATION SIG=3 METHOD=1 INTER MAXEVAL=2000 PRINT=0 
POSTHOC NOABORT 
 
$TABLE ID DV TIME 
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID KA K AMT TIME IPRED DV 
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
 
Trans 2: 
$PROB En-kompartment med absorpsjon 
 
$DATA test7.txt 
 
$INPUT ID AMT RATE DATE=DROP TIME CRCL=DROP WGT=DROP 
CONC=DV MDV DOSE SEX=DROP DAY=DROP PASN=DROP 
 
$SUBROUTINE ADVAN2 TRANS2 
 
$PK 
TVCL=THETA(1) 
CL=TVCL*EXP(ETA(1)) 
TVVD=THETA(2) 
V=TVVD*EXP(ETA(2)) 
TVKA=THETA(3) 
KA=TVKA*EXP(ETA(3)) 
 
; THE FOLLOWING ARE REQUIRED BY PREDPP 
 
K=CL/V 
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S2=V 
 
$ERROR 
IPRED=F 
Y=F+ERR(1) 
 
$THETA 
(0, 3) 
(0, 6) 
(0, 0.05) 
 
$OMEGA 
0.00001 0.00001 0.00001 
 
$SIGMA 
0.5 
 
$ESTIMATION SIG=3 METHOD=1 INTER MAXEVAL=2000 PRINT=0 
POSTHOC 
 
$TABLE ID DV TIME 
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID KA K AMT TIME DV IPRED 
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
 
7.3.2 2-compartment with first-order absorption 
$PROB To-kompartment med absorpsjon 
 
$DATA test7.txt 
 
$INPUT ID AMT RATE DATE=DROP TIME CRCL=DROP WGT=DROP 
CONC=DV MDV DOSE=DROP SEX=DROP DAY=DROP PASN=DROP 
 
$SUBROUTINE ADVAN4 TRANS4 
 
$PK 
CL=THETA(1)*EXP(ETA(1)) 
V2=THETA(2)*EXP(ETA(2)) 
Q=THETA(3)*EXP(ETA(3)) 
V3=THETA(4)*EXP(ETA(4)) 
KA=THETA(5)*EXP(ETA(5)) 
 
; THE FOLLOWING ARE REQUIRED BY PREDPP 
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K=CL/V2 
K23=Q/V2 
K32=Q/V3 
S2=V2 
S3=V3 
 
$ERROR 
IPRED=F 
Y=F+F*ERR(1)+ERR(2) 
 
$THETA 
(0, 12, 50) 
(0, 18.5, 100) 
(0, 9.82, 50) 
(0, 44.4, 100) 
(0, 0.287) 
 
$OMEGA 
0.01 0.01 0.01 0.01 0.01 
 
$SIGMA 
0.15 0.001 
 
$ESTIMATION SIG=3 METHOD=1 INTER MAXEVAL=2000 PRINT=0 
POSTHOC NOABORT 
 
$TABLE ID DV TIME 
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID KA K AMT TIME IPRED DV 
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
 
7.3.3 3-compartment with first-order absorption 
$PROB Tre-kompartment med absorpsjon 
 
$DATA test7.txt 
 
$INPUT ID AMT RATE DATE=DROP TIME CRCL=DROP WGT=DROP 
CONC=DV MDV DOSE=DROP SEX=DROP DAY=DROP PASN=DROP 
 
$SUBROUTINE ADVAN12 TRANS4 
 
$PK 
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CL=THETA(1)*EXP(ETA(1)) ;Clearance 
V2=THETA(2)*EXP(ETA(2)) ;central volume 
Q3=THETA(3)*EXP(ETA(3)) ;intercompartmental clearance (central and periph 1) 
V3=THETA(4)*EXP(ETA(4)) ;peripheral 1 volume 
Q4=THETA(5)*EXP(ETA(5)) ;intercompartmental clearance (central and periph 2) 
V4=THETA(6)*EXP(ETA(6)) ;peripheral 2 volume 
KA=THETA(7)*EXP(ETA(7)) ;absorption rate constant 
 
K=CL/V2 
K23=Q3/V2 
K32=Q3/V3 
K24=Q4/V2 
K42=Q4/V4 
KA=KA 
 
S2=V2 
S3=V3 
S4=V4 
 
$ERROR 
IPRED=F 
Y=F+F*ERR(1)+ERR(2) 
 
$THETA 
(0, 1) 
(0, 10) 
(0, 0.5) 
(0, 15) 
(0, 2) 
(0, 5) 
(0, 0.1) 
 
$OMEGA 
0.01 0.01 0.01 0.01 0.01 0.01 0.01 
 
$SIGMA 
0.5 0.5 
 
$ESTIMATION SIG=3 METHOD=1 INTER MAXEVAL=2000 PRINT=0 
POSTHOC NOABORT 
 
$TABLE ID DV TIME 
NOPRINT ONEHEADER FILE=table.txt 
 
$TABLE ID KA K AMT TIME IPRED DV 
FIRSTONLY NOPRINT ONEHEADER NOAPPEND FILE=etatable.txt 
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7.3.4 Jackknife 
Pasient 
fjernet 
Variabler 
Clearance 
(CL) 
Central 
Volume 
(V2) 
Intercompartmental 
Clearance (Q) 
Peripheral 
Volume 
(V3) 
Absorption 
rate 
constant 
(KA) 
Absorption 
time lag 
(ALAG) 
1 12 63.1 7.19 314 0.287 0.661 
2 12 61.7 7.21 316 0.287 0.661 
3 12 59.4 7.21 304 0.287 0.661 
4 12 59.4 7.21 304 0.287 0.661 
5 12 59.4 7.21 304 0.287 0.661 
6 12.1 63.5 7.07 317 0.287 0.661 
7 12.2 67 7.57 301 0.287 0.661 
8 12 59.4 7.21 304 0.287 0.661 
9 12 59.4 7.21 304 0.287 0.661 
10 12 59.4 7.21 304 0.287 0.661 
11 12 59.4 7.21 304 0.287 0.661 
12 12.1 65 7.18 312 0.287 0.661 
13 12 59.4 7.21 304 0.287 0.661 
14 12 59.4 7.21 304 0.287 0.661 
15 12 59.4 7.21 304 0.287 0.661 
16 12.3 60 6.88 346 0.287 0.661 
17 12 67.1 6.93 304 0.287 0.661 
18 12.2 79.8 5.54 273 0.287 0.661 
19 12 59.4 7.21 304 0.287 0.661 
20 12 59.4 7.21 306 0.287 0.661 
21 12 59.4 7.21 311 0.287 0.661 
22 12 59.4 7.21 304 0.287 0.661 
23 12 59.1 7.07 328 0.287 0.661 
24 12 59.4 7.21 304 0.287 0.661 
25 12.1 68.4 7.69 314 0.287 0.661 
26 12 59.4 7.21 304 0.287 0.661 
27 12 59.4 7.21 304 0.287 0.661 
28 12 58.4 6.74 312 0.287 0.661 
29 12 59.4 7.21 304 0.287 0.661 
30 12 59.4 7.21 323 0.287 0.661 
31 12 59.4 7.21 317 0.287 0.661 
32 12 59.4 7.21 319 0.287 0.661 
33 12 59.4 7.21 304 0.287 0.661 
34 12.1 64.2 7.21 319 0.287 0.661 
35 12 59.4 7.21 304 0.287 0.661 
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36 12 59.4 7.21 309 0.287 0.661 
37 12.2 63.9 7.55 311 0.287 0.661 
38 12 59.4 7.21 304 0.287 0.661 
39 12 59.5 7.2 319 0.287 0.661 
40 12 63.1 7.17 316 0.287 0.661 
41 12 59.4 7.21 304 0.287 0.661 
42 12 59.4 7.21 304 0.287 0.661 
43 12 59.4 7.21 304 0.287 0.661 
44 12 59.4 7.21 304 0.287 0.661 
45 12 59.4 7.21 304 0.287 0.661 
46 12 59.4 7.21 304 0.287 0.661 
47 12 59.4 7.21 323 0.287 0.661 
48 12 59.4 7.21 308 0.287 0.661 
49 12 71.3 7.94 325 0.287 0.661 
50 12.1 59.7 7.16 322 0.287 0.661 
51 12 61.5 7.35 318 0.287 0.661 
52 12 59.4 7.21 304 0.287 0.661 
53 12 59.4 7.21 304 0.287 0.661 
54 12 59.4 7.21 312 0.287 0.661 
55 12 59.4 7.21 304 0.287 0.661 
56 12 59.4 7.21 304 0.287 0.661 
57 12 59.4 7.21 304 0.287 0.661 
58 12 59.4 7.21 304 0.287 0.661 
59 12 59.4 7.21 304 0.287 0.661 
60 12 59.4 7.21 304 0.287 0.661 
61 12 59.4 7.21 304 0.287 0.661 
62 12 59.4 7.21 304 0.287 0.661 
63 12 59.4 7.21 304 0.287 0.661 
64 12 59.4 7.21 304 0.287 0.661 
65 12 59.4 7.21 304 0.287 0.661 
66 12 59.4 7.21 304 0.287 0.661 
67 12 59.4 7.21 304 0.287 0.661 
68 12 59.4 7.21 304 0.287 0.661 
69 12 59.4 7.21 304 0.287 0.661 
70 12 59.4 7.21 304 0.287 0.661 
71 12 59.4 7.21 304 0.287 0.661 
72 12 59.4 7.21 304 0.287 0.661 
73 12 59.4 7.21 304 0.287 0.661 
74 12 59.4 7.21 304 0.287 0.661 
75 12 59.4 7.21 304 0.287 0.661 
76 12 59.4 7.21 304 0.287 0.661 
77 12 59.4 7.21 304 0.287 0.661 
78 12 59.4 7.21 304 0.287 0.661 
79 12 59.4 7.21 304 0.287 0.661 
80 12 59.4 7.21 304 0.287 0.661 
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81 12 59.4 7.21 304 0.287 0.661 
82 12 59.4 7.2 326 0.287 0.661 
83 12 59.4 7.21 304 0.287 0.661 
84 12 59.4 7.21 304 0.287 0.661 
85 12 59.4 7.21 304 0.287 0.661 
86 12 59.4 7.21 316 0.287 0.661 
87 12 59.4 7.21 305 0.287 0.661 
88 12 59.4 7.21 304 0.287 0.661 
89 12 59.4 7.21 304 0.287 0.661 
90 12 59.4 7.21 304 0.287 0.661 
91 12 59.4 7.21 304 0.287 0.661 
92 12 59.4 7.21 304 0.287 0.661 
93 12 59.4 7.21 304 0.287 0.661 
94 12 59.4 7.21 304 0.287 0.661 
95 12 59.4 7.21 304 0.287 0.661 
96 12 59.4 7.21 304 0.287 0.661 
97 12 59.4 7.21 304 0.287 0.661 
98 12 59.4 7.21 304 0.287 0.661 
99 12 59.4 7.21 304 0.287 0.661 
100 12 59.4 7.21 304 0.287 0.661 
101 12 59.4 7.21 304 0.287 0.661 
102 12 59.4 7.21 311 0.287 0.661 
103 12 59.4 7.21 304 0.287 0.661 
104 12 59.4 7.21 309 0.287 0.661 
105 12 59.4 7.21 304 0.287 0.661 
106 12 59.4 7.21 304 0.287 0.661 
107 12 59.4 7.21 304 0.287 0.661 
108 12 59.4 7.21 304 0.287 0.661 
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7.3.5 Scatterplot of WRES vs. PRED 
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Scatterplot of WRES vs PRED
WRES = 0.590 - 0.147 PRED, R-Sq = 2.9%
 
7.3.6 Scatterplot of WRES vs. IPRE 
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Scatterplot of WRES vs IPRE
WRES = - 0.332 + 0.151 IPRE, R-Sq = 8.4%
 
 
